Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities downgraded the rating on the stock to a Sell and gave it a $1.00 price target.
Tazeen Ahmad has given his Sell rating due to a combination of factors impacting Neumora Therapeutics, Inc. The primary concern is the delay in the timeline for their major depressive disorder (MDD) program, with key updates now expected in 2026 instead of 2025. This delay follows a negative outcome in a phase 3 trial, which has led the company to revise its clinical protocols, but the effectiveness of these changes remains uncertain.
Additionally, the discontinuation of the phase 2 study for bipolar depression has removed potential value from the company’s portfolio, as they shift focus to the MDD program. The rest of Neumora’s pipeline still requires clinical validation, with some assets potentially entering the market late compared to competitors. These factors contribute to a more conservative outlook on the company’s future performance.